(SRT3) Sartorius Aktiengesellschaft - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: XETRA (Germany) | Market Cap: 15.958m EUR | Total Return: 5.7% in 12m
Avg Turnover: 20.3M
EPS Trend: -52.2%
Qual. Beats: 0
Rev. Trend: -13.9%
Qual. Beats: 0
Warnings
P/E ratio 98.3
Tailwinds
No distinct edge detected
Sartorius Aktiengesellschaft is a global provider of laboratory and bioprocess technologies headquartered in Göttingen, Germany. The company operates through two primary segments: Bioprocess Solutions, which focuses on the manufacturing of biopharmaceuticals, and Lab Products & Services, which supports life science research and quality control.
The company’s portfolio includes bioreactors, cell culture media, fluid management systems, and high-precision laboratory instruments such as weighing and filtration tools. As a key supplier to the biopharmaceutical industry, Sartorius benefits from the sectors shift toward single-use technologies, which reduce cross-contamination risks and increase production flexibility compared to traditional stainless-steel systems.
The business model relies heavily on recurring revenue from consumables, which often account for a high proportion of total sales as biopharmaceutical production scales. For deeper insights into these revenue streams and valuation metrics, consider reviewing the detailed financial breakdowns on ValueRay.
Founded in 1870, the firm serves diverse markets including cell and gene therapy, applied industries, and academic research. It maintains a significant presence in the XETRA exchange under the ticker SRT3, operating within the Health Care Equipment GICS sub-industry.
- Biopharmaceutical manufacturing capital expenditure recovery drives long-term equipment demand
- Inventory destocking cycles in bioprocess solutions impact short-term revenue growth
- Expansion into cell and gene therapy markets increases high-margin service revenue
- High interest rates and financing costs constrain biotech research and development spending
- Strategic acquisitions in analytical technologies influence balance sheet and margin profiles
| Net Income: 162.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.11 > 1.0 |
| NWC/Revenue: -5.34% < 20% (prev 19.69%; Δ -25.03% < -1%) |
| CFO/TA 0.07 > 3% & CFO 709.1m > Net Income 162.7m |
| Net Debt (3.93b) to EBITDA (997.3m): 3.94 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.1m) vs 12m ago -0.34% < -2% |
| Gross Margin: 45.59% > 18% (prev 0.45%; Δ 4.51k% > 0.5%) |
| Asset Turnover: 35.57% > 50% (prev 34.06%; Δ 1.51% > 0%) |
| Interest Coverage Ratio: 2.39 > 6 (EBITDA TTM 997.3m / Interest Expense TTM 240.7m) |
| A: -0.02 (Total Current Assets 1.92b - Total Current Liabilities 2.11b) / Total Assets 9.87b |
| B: 0.24 (Retained Earnings 2.41b / Total Assets 9.87b) |
| C: 0.06 (EBIT TTM 574.1m / Avg Total Assets 9.99b) |
| D: 0.41 (Book Value of Equity 2.48b / Total Liabilities 5.98b) |
| Altman-Z'' = 1.49 = BB |
| DSRI: 0.94 (Receivables 366.6m/378.9m, Revenue 3.55b/3.44b) |
| GMI: 0.99 (GM 45.59% / 45.27%) |
| AQI: 1.01 (AQ_t 0.56 / AQ_t-1 0.55) |
| SGI: 1.03 (Revenue 3.55b / 3.44b) |
| TATA: -0.06 (NI 162.7m - CFO 709.1m) / TA 9.87b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at EUR 233.00 with a total of 37,039 shares traded.
Over the past week, the price has changed by +6.10%,
over one month by +6.49%,
over three months by -1.72% and
over the past year by +5.65%.
Sartorius Aktiengesellschaft has no consensus analysts rating.
P/E Trailing = 98.3404
P/E Forward = 42.5532
P/S = 4.4899
P/B = 5.8882
P/EG = 0.9353
Revenue TTM = 3.55b EUR
EBIT TTM = 574.1m EUR
EBITDA TTM = 997.3m EUR
Long Term Debt = 3.17b EUR (from longTermDebt, last quarter)
Short Term Debt = 963.8m EUR (from shortTermDebt, last quarter)
Debt = 4.51b EUR (from shortLongTermDebtTotal, last quarter) + Leases 204.4m
Net Debt = 3.93b EUR (calculated: Debt 4.51b - CCE 573.8m)
Enterprise Value = 19.9b EUR (16.0b + Debt 4.51b - CCE 573.8m)
Interest Coverage Ratio = 2.39 (Ebit TTM 574.1m / Interest Expense TTM 240.7m)
EV/FCF = 74.89x (Enterprise Value 19.9b / FCF TTM 265.6m)
FCF Yield = 1.34% (FCF TTM 265.6m / Enterprise Value 19.9b)
FCF Margin = 7.47% (FCF TTM 265.6m / Revenue TTM 3.55b)
Net Margin = 4.58% (Net Income TTM 162.7m / Revenue TTM 3.55b)
Gross Margin = 45.59% ((Revenue TTM 3.55b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 46.10% (prev 42.73%)
Tobins Q-Ratio = 2.01 (Enterprise Value 19.9b / Total Assets 9.87b)
Interest Expense / Debt = 5.34% (Interest Expense 240.7m / Debt 4.51b)
Taxrate = 27.03% (30.0m / 111.0m)
NOPAT = 418.9m (EBIT 574.1m * (1 - 27.03%))
Current Ratio = 0.91 (Total Current Assets 1.92b / Total Current Liabilities 2.11b)
Debt / Equity = 1.65 (Debt 4.51b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 3.94 (Net Debt 3.93b / EBITDA 997.3m)
Debt / FCF = 14.80 (Net Debt 3.93b / FCF TTM 265.6m)
Total Stockholder Equity = 2.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.63% (Net Income 162.7m / Total Assets 9.87b)
RoE = 6.05% (Net Income TTM 162.7m / Total Stockholder Equity 2.69b)
RoCE = 9.80% (EBIT 574.1m / Capital Employed (Equity 2.69b + L.T.Debt 3.17b))
RoIC = 4.80% (NOPAT 418.9m / Invested Capital 8.72b)
WACC = 7.06% (E(16.0b)/V(20.5b) * Re(7.95%) + D(4.51b)/V(20.5b) * Rd(5.34%) * (1-Tc(0.27)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 51.85 | Cagr: 0.41%
[DCF] Terminal Value 73.10% ; FCFF base≈434.3m ; Y1≈380.8m ; Y5≈307.7m
[DCF] Fair Price = 28.94 (EV 4.94b - Net Debt 3.93b = Equity 1.01b / Shares 34.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -52.15 | EPS CAGR: -10.57% | SUE: -0.60 | # QB: 0
Revenue Correlation: -13.85 | Revenue CAGR: -0.65% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.37 | Chg30d=-3.09% | Revisions=-33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.28 | Chg30d=-2.56% | Revisions=-11% | Analysts=5
EPS current Year (2026-12-31): EPS=5.35 | Chg30d=-1.90% | Revisions=-33% | GrowthEPS=+11.8% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=6.38 | Chg30d=-1.88% | Revisions=-37% | GrowthEPS=+19.2% | GrowthRev=+9.4%
[Analyst] Revisions Ratio: -37%